论文部分内容阅读
目的：探讨原发性肝癌、肝硬化患者血浆脂质过氧化物（ＬＰＯ）和红细胞超氧化物歧化酶（ＳＯＤ）活性变化及其临床意义。方法：测定３０例原发性肝癌和３２例肝硬化患者及４０例正常人血浆ＬＰＯ和红细胞ＳＯＤ活性。结果：原发性肝癌、肝硬化患者血浆ＬＰＯ含量分别为（４．６１±０．６９）μｍｏｌ／Ｌ和（５．３４±１．３３）μｍｏｌ／Ｌ，较正常对照组〔（２．４８±０．３５）μｍｏｌ／Ｌ〕明显升高（Ｐ均＜０．００１）；２组红细胞ＳＯＤ活性分别为（１６９５．５±２２９．７）Ｕ／ｇ和（２６５１．５±４４５．６）Ｕ／ｇ，较正常对照组〔（３３３０．２±５５２．２）Ｕ／ｇ〕明显降低，Ｐ均＜０．００１；进一步比较原发性肝癌患者红细胞ＳＯＤ活性较肝硬化患者亦明显降低（Ｐ＜０．０１）。结论：肝硬化时脂质过氧化作用增强造成的细胞损害可能是原发性肝癌的发病机制之一；红细胞ＳＯＤ活性变化可望作为肝硬化转变为肝癌的早期临床诊断的辅助指标
Objective: To investigate the changes of plasma lipid peroxide (LPO) and red blood cell superoxide dismutase (SOD) activity in patients with primary liver cancer and liver cirrhosis and their clinical significance. Methods: Plasma LPO and erythrocyte SOD activity were measured in 30 patients with primary liver cancer, 32 patients with cirrhosis, and 40 normal controls. Results: The plasma LPO levels in patients with primary liver cancer and liver cirrhosis were (4.61±0.69) μmol/L and (5.34±1.33) μmol/L, respectively, compared with the normal control group ((2.48). ± 0.35 μmol/L] was significantly increased (P <0.001); the red blood cell SOD activity was (1695.5 ± 229.7) U/g and (2651.5 ± 445.6), respectively. U/g was significantly lower than normal control group (3330.2±552.2 U/g), P<0.001; further comparison of red blood cell SOD activity in primary liver cancer patients was also significantly lower than in liver cirrhosis patients ( P<0.01). Conclusion: Cell damage caused by enhanced lipid peroxidation during liver cirrhosis may be one of the pathogenesis of primary hepatocellular carcinoma; changes in red blood cell SOD activity may be expected as an auxiliary indicator for early clinical diagnosis of liver cirrhosis and liver cancer.